Why FDA clearance matters for DiaSorin stock

Published on 10/15/2026 at 10:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock stood at EUR 77.82 at Lang & Schwarz on October 15, 2026, versus EUR 78.16 in Milan. First-half 2026 revenue was EUR 602 million, flat.

Regulatory progress and quarterly dates

The FDA approved DiaSorin's automated Parvovirus B19 tests on October 13, 2026.
First-half 2026 revenue reached EUR 602 million at constant exchange rates.
DiaSorin stock traded at EUR 77.82 at 10:45 a.m. CEST at Lang & Schwarz on October 15, 2026.
Third-quarter 2026 results are scheduled for November 6, 2026.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin (ISIN IT0003492391) was quoted at EUR 77.82 at Lang & Schwarz on October 15, 2026 at 10:45 a.m. CEST. The latest company-specific catalyst was the U.S. Food and Drug Administration approval of automated Parvovirus B19 serology tests for the LIAISON XL system, reported on October 13, 2026 by FTA Online.

FDA clearance adds a product milestone

The approval covers the first fully automated tests for Parvovirus B19 IgM and IgG serology on DiaSorin's LIAISON XL platform. The event adds a concrete regulatory milestone while the stock remains below the EUR 80.00 technical resistance level cited by FTA Online on October 14, 2026.

DiaSorin's second-quarter 2026 revenue grew 4 percent at constant exchange rates, compared with flat growth in the first quarter. The first half produced revenue of EUR 602 million, flat at constant exchange rates and down 3 percent at current rates, according to Yahoo Finance.

What does the clearance mean for margins?

The answer depends on execution across DiaSorin's diagnostic platforms. Adjusted EBITDA reached EUR 194 million in the first half of 2026, down 7 percent at constant exchange rates, while the adjusted EBITDA margin was 32 percent. Management confirmed full-year 2026 guidance for revenue growth of 5 percent to 6 percent and an adjusted EBITDA margin of 32 percent to 33 percent in the earnings call.

Three dated steps define the story

On October 2, 2026, Margherita Sacerdoti was appointed Investor Relations and ESG Senior Director, according to Worldnews. On October 13, the FDA approval added the Parvovirus B19 test milestone. On October 15, the Lang & Schwarz quote stood at EUR 77.82.

The next dated company event is the release of third-quarter 2026 results on November 6, 2026, according to FTA Online.

Stock holds a product and margin test

DiaSorin's current setup combines a newly approved assay with a recovery in second-quarter growth and a confirmed full-year margin range. The November results will show whether new product placements and better operating leverage can offset the continuing pressure from China and currency effects.

DiaSorin was trading at EUR 77.82 at Lang & Schwarz on October 15, 2026 at 10:45 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.